Harry Wilcox

Harry joined Flagship Ventures in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. His career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partnerswhere he was the founding CFO and General Partner, and prior to that, Charles River Ventures. Most recently he has served as CFO and then Sr. VP Corporate Development forEXACT Sciences (NASDAQ:EXAS), one of Flagship’s portfolio companies. In addition to EXACT Sciences, Harry led an active consulting practice which included roles as interim CEO of two biotech companies: Thrasos Therapeutics and Biostratum. Prior to this, Harry was Executive Vice President, Chief of Finance and Corporate Development of Pyrosequencing, a publicly-held European biotech company. Earlier, he had been the President and Chief Executive Officer of Cambridge NeuroScience, Inc. (NASDAQ:CNSI) until its sale to CeNeS Pharmaceuticals, and before that Sr. VP Business Development and CFO of Cellcor. As COO and General Partner at Flagship Ventures, Harry is responsible for the operational management of Flagship’s VentureLabsTM unit, serves as a member of Flagship’s investment committee, and oversees the firm’s financial operations and LP relations/fundraising. He was a board member of Accuri Cytometers prior to its successful sale to Becton Dickinson. He also plays a role as board member or advisor to select portfolio companies and is currently a board member of Black Duck, Celexion, Seahorse Bioscience, Seventh Sense Biosystems, Tangent Medical Technologies, Inc. and T2 Biosystems.